Neuroprotective and neurorestorative therapies for the treatment of Parkinson's disease;Terapias neuroprotectoras y neurorestauradoras en el tratamiento de la enfermedad de Parkinson

Anales del Sistema Sanitario de Navarra

Volumn 29, Issue 3, 2006, Pages 325-335

  Garbayo, E ^a   Aymerich, M S ^a   Ansorena, E ^a   Lanciego, J L ^a   Blanco Prieto, María José ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

GDNF; Microspheres; Neuroproteccion; Neuroregeneration; Parkinson's disease

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; MICROSPHERE;

BRAIN DEPTH STIMULATION; CELL THERAPY; CLINICAL FEATURE; DISEASE COURSE; DRUG DELIVERY SYSTEM; HUMAN; NEUROPROTECTION; PARKINSON DISEASE; REVIEW; STEREOTAXIC SURGERY;

GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLOBUS PALLIDUS; HUMANS; LOCUS COERULEUS; MEDULLA OBLONGATA; MICROSPHERES; NERVE REGENERATION; NEUROPROTECTIVE AGENTS; NEUROSURGICAL PROCEDURES; PARKINSON DISEASE; SUBSTANTIA NIGRA; THALAMUS;

EID: 33846300313     PISSN: 11376627     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. SEGURA T, GALINDO MF, RALLO-GUTIERREZ B, CEÑA V, JORDÁN J. DIANAS farmacológicas en las enfermedades neurodegenerativas. Rev Neurol 2003; 36: 1047-1057.
2. DAUER W, PRZEDBORSKI S. Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909.
3. LANG AE, LOZANO AM. Parkinson's disease. Second of two parts. N Engl J Med 1998; 339: 1130-1143.
4. LANG AE, LOZANO AM. Parkinson's disease. First of two parts. N Engl J Med 1998; 339: 1044-1053.
5. MICHELL AW, LEWIS SJ, FOLTYNIE T, BARKER RA. Biomarkers and Parkinson's disease. Brain 2004; 127: 1693-1705.
6. SAVITT JM, DAWSON VL, DAWSON TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006; 116: 1744-1754.
7. RASCOL O, PAYOUX P, ORY F, FERREIRA JJ, BREFEL-COURBON C, MONTASTRUC JL. Limitations of current Parkinson's disease therapy. Ann Neurol 2003; 53 Suppl 3: S3-12; discussion S12-15.
8. ESPEJO EF, MONTORO RJ, ARMENGOL JA, LOPEZ-BARNEO J. Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates. Neuron 1998; 20: 197-206.
9. ROSENBLAD C, MARTINEZ-SERRANO A, BJORKLUND A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 1998; 82: 129-137.
10. SHINGO T, DATE I, YOSHIDA H, OHMOTO T. Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF-producing cells in a rat model of Parkinson's disease. J Neurosci Res 2002; 69: 946-954.
11. KORSCHING S. The neurotrophic factor concept: a reexamination. J Neurosci 1993; 13: 2739-2748.
12. ALEXI T, BORLONGAN CV, FAULL RL, WILLIAMS CE, CLARK RG, GLUCKMAN PD et al. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Prog Neurobiol 2000; 60: 409-470.
13. BECK KD, VALVERDE J, ALEXI T, POULSEN K, MOFFAT B, VANDLEN RA et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 1995; 373: 339-341.
14. TOMAC A, LINDQVIST E, LIN LF, OGREN SO, YOUNG D, HOFFER BJ et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995; 373: 335-339.
15. GASH DM, ZHANG Z, OVADIA A, CASS WA, YI A, SIMMERMAN L et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996; 380: 252-255.
16. HENDERSON CE, PHILLIPS HS, POLLOCK RA, DAVIES AM, LEMEULLE C, ARMANINI M et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 1994; 266: 1062-1064.
17. OPPENHEIM RW, HOUENOU LJ, JOHNSON JE, LIN LF, LI L, LO AC et al. Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF. Nature 1995; 373: 344-346.
18. KISHIMA H, POYOT T, BLOCH J, DAUGUET J, CONDE F, DOLLE F et al. Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons. Neurobiol Dis 2004; 16: 428-439.
19. MCBRIDE JL, KORDOWER JH. Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF. Prog Brain Res 2002; 138: 421-432.
20. JOLLIVET C, AUBERT-POUESSEL A, CLAVREUL A, VENIER-JULIENNE MC, REMY S, MONTERO-MENEI CN et al. Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease. Biomaterials 2004; 25: 933-942.
21. GARBAYO E, ANSORENA E, AYMERICH MS, LANCIEGO JL, BLANCO-PRIETO MJ. Controlled drug delivery to the brain: an overview. Hand Book of Particulate Drug delivery. American Scientific Publishers, NY 2006; En prensa.
22. GARBAYO E, AYMERICH MS, ANSORENA E, LANCIEGO JL, BLANCO-PRIETO MJ. Microencapsulated recombinant GDNF: in vitro characterization and in vivo efficacy in a rat model of Parkinson's disease. VIIth Spanish-Portuguese Local Chapter of the Controlled Release Society (SPCL-CRS) Pamplona (Spain) 2006; 85-86.
23. GRONDIN R, ZHANG Z, YI A, CASS WA, MASWOOD N, ANDERSEN AH et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 2002; 125: 2191-2201.
24. GILL SS, PATEL NK, HOTTON GR, O'SULLIVAN K, MCCARTER R, BUNNAGE M et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003; 9: 589-595.
25. PATEL NK, BUNNAGE M, PLAHA P, SVENDSEN CN, HEYWOOD P, GILL SS. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a twoyear outcome study. Ann Neurol 2005; 57: 298-302.
26. SLEVIN JT, GERHARDT GA, SMITH CD, GASH DM, YOUNG AB. Reply: GDNF poses troubling questions for doctors, drug maker. Ann Neurol 2006; 59: 989-990.
27. SHERER TB, FISKE BK, SVENDSEN CN, LANG AE, LANGSTON JW. Crossroads in GDNF therapy for Parkinson's disease. Mov Disord 2006; 21: 136-141.
28. VEZIERS J, LESOURD M, JOLLIVET C, MONTERO-MENEI C, BENOIT JP, MENEI P. Analysis of brain biocompatibility of drug-releasing biodegradable microspheres by scanning and transmission electron microscopy. J Neurosurg 2001; 95: 489-494.
29. MENEI P, BENOIT JP. Implantable drug-releasing biodegradable microspheres for local treatment of brain glioma. Acta Neurochir Suppl 2003; 88: 51-55.
30. ARICA B, KAS HS, MOGHDAM A, AKALAN N, HINCAL AA. Carbidopa/levodopa-loaded biodegradable microspheres: in vivo evaluation on experimental Parkinsonism in rats. J Control Release 2005; 102: 689-697.
31. MCRAE A, DAHLSTROM A. Transmitter-loaded polymeric microspheres induce regrowth of dopaminergic nerve terminals in striata of rats with 6-OHDA induced parkinsonism. Neurochem Int 1994; 25: 27-33.
32. MCRAE A, LING EA, HJORTH S, DAHLSTROM A, MASON D, TICE T. Catecholamine- containing biodegradable microsphere implants as a novel approach in the treatment of CNS neurodegenerative disease. A review of experimental studies in DA-lesioned rats. Mol Neurobiol 1994; 9: 191-205.